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Abstract
Shikimate kinase (SK), which catalyzes the specific phosphorylation of the 3-hydroxyl group of shikimic acid in the presence
of ATP, is the enzyme in the fifth step of the shikimate pathway for biosynthesis of aromatic amino acids. This pathway is
present in bacteria, fungi, and plants but absent in mammals and therefore represents an attractive target pathway for the
development of new antimicrobial agents, herbicides, and antiparasitic agents. Here we investigated the detailed structure–
activity relationship of SK from Helicobacter pylori (HpSK). Site-directed mutagenesis and isothermal titration calorimetry
studies revealed critical conserved residues (D33, F48, R57, R116, and R132) that interact with shikimate and are therefore
involved in catalysis. Crystal structures of HpSK?SO4, R57A, and HpSKNshikimate-3-phosphateNADP show a characteristic
three-layer architecture and a conformationally elastic region consisting of F48, R57, R116, and R132, occupied by shikimate.
The structure of the inhibitor complex, E114AN162535, was also determined, which revealed a dramatic shift in the elastic
LID region and resulted in conformational locking into a distinctive form. These results reveal considerable insight into the
active-site chemistry of SKs and a selective inhibitor-induced-fit mechanism.
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Introduction
In recent years, major problematic bacterial infections have
been described for methicillin-resistant Staphylococcus aureus, Entero-
coccus faecium, Staphylococcus pneumonia, Klebsiella species, Acinetobacter
baumannii, Pseudomonas aeruginosa, Mycobacterium tuberculosis, and
Escherichia coli [1–3]. The high prevalence of resistant bacteria
and complex resistance, including multidrug-resistant pathogens,
has been of particular concern. There are, however, limited
antibacterial therapeutic options for the treatment of nosocomial
infections for multidrug-resistant Gram-negative bacteria [4].
Health professionals are very aware of the urgent need for novel
antibiotic agents against Gram-negative bacteria [5]. Despite a
growing need for new and more effective antibiotics (or other
means) to cure problematic bacterial infections, few new agents
have been found in recent years owing to a substantial decline in
research and development investment in the face of a challenging
economic climate [6,7].
The shikimate pathway is comprised of seven enzymatic
components that convert erythrose 4-phosphate and phospho-
enolpyruvate into chorismate, for subsequent synthesis of aromatic
compounds [8]. This pathway is present in microbial cells,
apicomplexan parasites, and plants but is absent in animals; this
makes it an attractive target pathway for the development of new
antimicrobial agents, herbicides, and antiparasitic agents [9–18].
Of note, 5-enolpyruvylshikimate 3-phosphate synthase (the sixth
enzyme in the shikimate pathway) has been successfully targeted
with glyphosate, one of the world’s best-selling herbicides [19,20].
Disruption in M. tuberculosis of aroK, the gene encoding shikimate
kinase (SK, EC 2.7.1.71), the fifth enzyme of the shikimate
pathway, further suggests that this pathway is essential for
antimicrobial drug discovery [21].
SK catalyzes the specific phosphorylation of the 3-hydroxyl
group of shikimic acid, using ATP as a co-substrate. Several SK
structures are available (from E. coli, Erwinia chrysanthemi,
Campylobacter jejuni, Aquifex aeolicus and Arabidopsis thaliana [22–
27]), and also from two important pathogens, M. tuberculosis and
Helicobacter pylori (MtSK and HpSK, respectively) [28–33]. SKs
belong to a class of P-loop kinases that share a homologous a-b-a
fold [23,34]. These structures have an active site created by
conserved residues and occupied by ATP and shikimate. The
occupancy of this site by substrates/products is associated with
inducing an open-to-closed conformational change by a flexible
loop, and domain movement for SKs [32]. Such movement, as is
the case for many other kinases, is essential for catalytic turnover
[34]. Understanding the critical residues involved in ligand
binding and conformational flexibility is therefore essential in
aiding design of potential selective inhibitors [35,36].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33481The likelihood of HpSK as a target enzyme for potential drug
and herbicide discovery prompted us to investigate the detailed
structure-activity relationship of the binding pocket. Here, we
report the crystal structures of HpSK?SO4, R57A, and HpSKN
shikimate-3-phosphate (S3P)NADP, which reveal that three con-
served Arg residues (R57, R116, R132), the side chain of D33, and
the aromatic ring of F48 are involved in binding to shikimate. We
also determined the X-ray structure of the E114A mutant SK-
inhibitor complex using a selective inhibitor (NSC162535;
IC50=4.9 mM) identified from virtual docking analysis. Site-
directed mutagenesis and isothermal titration calorimetry (ITC)
together revealed the key binding residues and a NSC162535/
induced-fit mechanism.
Results
Site-directed mutagenesis of shikimate-binding residues
One strategy to derive a specific selective inhibitor toward a
given P-loop kinase is to target the non-ATP-binding site, because
P-loop kinases possess a relatively conserved ATP site that
catalyzes the phosphotransfer reaction [34]. To this end, we
evaluated the shikimate-binding (SB) residues of HpSK. Structural
comparison of reported SKs show that the structures are mostly
homologous and contain a binding pocket consisting of nucleotide
and shikimate sites [22–27]. The most significant structural
deviation between the different structures is found in the LID
region, where an open/closed structural change occurs upon
ligand binding (Fig. S1). Based on the HpSK?shikimate?PO4
structure (1ZUI) [33], shikimate binds to residues from three
subsites: (i) CX, where a carboxyl moiety of shikimate makes
contact with R57, R116, and R132; (ii) OCORE, where two
hydroxyl groups of shikimate make contact with M10, D33, G79–
G81, and E114; and (iii) OLID, where a trans hydroxyl group of
shikimate interacts with V44, F48, E114, and R116. Of these
residues, D33, R57, G79–G81, R116, and R132 are strictly
conserved among all SKs, whereas the others (M10, V44, F48 and
E114) are relatively conserved (Fig. S2). Superposition analysis
showed that these residues essentially overlap, except for M10 and
E114. We therefore chose the following residues for site-directed
mutagenesis studies: strictly conserved residues (D33, R57, R116,
and R132) and moderately conserved residues (M10, F48, and
E114). Each of these sites was replaced with Ala or a more
conservative amino acid, as indicated in Table 1, and the resulting
mutant proteins were expressed in E. coli. After purification by
affinity chromatography, all mutants were analyzed by SDS-
PAGE; each migrated as a major band of apparent molecular
mass of approximately18 kDa, as expected. Each of the purified
proteins was subjected to size-exclusion chromatography. This
gave a single and sharp peak, suggesting each mutant existed in a
compact globular form.
We also performed differential scanning calorimetry (DSC)
experiments to evaluate the stability and unfolding of each of the
generated HpSK mutants. All HpSKs revealed a single transition
and fit well (Fig. S3). Wild-type HpSK showed a single transition
peak upon thermal unfolding, revealing a Tm value of 47uC
(Table S1). The other HpSK mutants also demonstrated a single
peak and had comparable Tm values (between 44uC and 50uC),
except for M10A (Tm=55uC) and D33A (Tm=41uC). It is noted
that purified D33A formed some precipitate after 1–2 weeks, in
line with a reduced thermal stability observed in the DSC results.
Enzymatic analysis of R57A, R116A and R132A revealed that
these mutants completely lost enzyme activity (Table 1), suggesting
that R57 and R132, from the CX site, are important in catalysis.
R116 is also noted to contribute to both the CX-site and OLID-site
interactions. Importantly, it has been suggested that R117 of
MtSK (corresponding to R116 of HpSK) may be the primary
residue involved in stabilizing the pentavalent phosphorus
transition-state intermediate [31]. Replacing Arg with Lys at
these sites (R57K, R116K, and R132K) did not restore any
detectable activity (Table 1). These results together suggest the
importance of three Arg residues in catalysis. F48 is located in the
OLID subsite and the mutant F48A exhibited no detectable
activity, although F48Y restored activity to 40%, indicating that
the aromatic ring of F48 contributes to catalytic activity. In
support of this view, we note that the aromatic ring of F48 makes
contact with R57 and other nearby residues (V44, E53, F56, and
P117) and forms stable interactions, thus ensuring R57 is in an
appropriate position to interact with shikimate. The side chain of
the other OLID residue, E114, faces the solvent, and E114A
retained 82% relative activity. For OCORE residues, D33A and
D33E showed loss of enzymatic activity, whereas M10A retained
38% relative activity.
We also investigated the kinetics of three mutants (M10A, F48Y
and E114A) that retained enzymatic activity. The apparent values
for Michaelis-Menten parameters were determined as follows:
M10A, Km (MgATP)=293642 mM, Km (shikimate)=135626 mM,
Vmax(MgATP)=2661 mmol/min/mg, Vmax(shikimate)=1661 mmol/
min/mg; F48Y, Km(MgATP)=231635 mM, Km(shikimate)=2916
99 mM, Vmax(MgATP)=1761 mmol/min/mg, Vmax(shikimate)=136
2 mmol/min/mg; E114A, Km(MgATP)=143618 mM, Km(shikimate)=
3967 mM, Vmax(MgATP)=2662 mmol/min/mg, Vmax(shikimate)=
2361 mmol/min/mg. As compared with the wild-type enzyme
(Km(MgATP)=101617 mM, Km(shikimate)=6068 mM, Vmax(MgATP)=
2661 mmol/min/mg, Vmax(shikimate)=2261 mmol/min/mg) [33],
M10A and F48Y exhibited lower affinity toward MgATP and
shikimate, respectively, in line with their lower relative activities
(Table 1). For the LID mutant E114A, it displayed very similar
kinetics as that of wildtype enzyme; there was only a slightly lower
affinity toward MgATP.
The crystal structure shows that D33 forms a hydrogen bond
with the 3-OH group of shikimate, which may increase the
Table 1. Comparison of the relative activities and Kd values of
wild-type and mutant HpSK.
Mutants
Relative
activity (%)
Km (mM) [ATP/
SKM] Kd (mM)
shikimate NSC162535
WT 100 101/60 0.3260.07 8.760.9
M10A 38 293/135 34672 . 8 60.8
D33A ND ND 962
D33E ND ND 1463
F48A ND ND ND
F48Y 40 231/291 5.260.4 1262
R57A 2 ND ND
R57K 2 ND 48631
E114A 82 143/39 0.3360.03 1164
R116A ND ND 962
R116K ND ND 4.860.6
R132A 5 ND ND
R132K ND ND ND
WT, wild type; ND, not detectable.
doi:10.1371/journal.pone.0033481.t001
Shikimate Kinase-Inhibitor Complex Structure
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group of shikimate. M10, on the other hand, shows limited
contacts with shikimate; thus, replacement with Ala at this site did
not completely eliminate the enzymatic activity. Together, our
results suggest that D33, F48, R57, R116, and R132 are critical for
enzymatic catalysis.
Comparison by ITC of the association between wild-type
or mutant HpSKs with shikimate or the inhibitor,
NSC162535
Using GEMDOCK docking algorithms, we modeled a pocket
that consists of the crucial SB residues (D33, F48, R57, R116,
R132) involved in catalysis, based on the HpSK?shikimate?PO4
structure (1ZUI) [33] to search for putative inhibitors [37,38] in
the Maybridge and NCI databases. We were thus able to identify a
potent competitive inhibitor, NSC162535 (IC50=4.9 mM; Ki
(shikimate)=1.8 mM; Ki (ATP)=1.9 mM; Fig. S5). We next
characterized the properties of those crucial residues for binding
to shikimate, using the ITC experiments. For the wild-type HpSK
(15 mM HpSK, 0.1 mM ADP, 0.5 mM Mg
2+), a clear shikimate
ITC pattern was observed, showing a high binding affinity to
shikimate (Kd=0.32 mM; Fig. 1 and Table 1). By contrast, D33A,
D33E, R57A, R57K, R116A, R116K, R132A and R132K
displayed no heat release. For F48, F48A lost binding activity,
whereas F48Y partially restored the shikimate binding activity
relative to F48A (Kd=5.2 mM), revealing that the aromatic ring
contributes towards binding to shikimate. Thus, the side chains of
D33 and three Arg residues (R57, R116, R132) as well as the
aromatic ring of F48 in HpSK are critically involved in shikimate
binding (Fig. 1A). We also evaluated the binding properties of the
two mutants, M10A and E114A, which exhibited a good portion
of enzymatic activity. M10A had a relatively low affinity for
shikimate (Kd=34mM; Fig. S4A), whereas E114A had a shikimate
binding affinity comparable to that of wild-type (Kd=0.33 mM;
Fig. 1A).
Figure 1. Binding properties of HpSK mutants. Isothermal titration calorimetry data showing, (A) the titration of shikimate into wild-type, F48Y,
and E114A, and (B) the titration of NSC162535 into wild-type, F48Y, and R116K. In each panel, the upper portion shows raw data for the titration, and
the lower portion shows the normalized, integrated binding isotherm together with the fitted binding curve.
doi:10.1371/journal.pone.0033481.g001
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to each of the HpSK mutants (Fig. 1B, Fig. S4B, and Table 1). The
wild-type enzyme had detectable binding affinity for NSC162535
(Kd=5.2 mM). With respect to the critical residues (D33, F48, R57,
R116,R132),the mutantsF48A,R57A,R132A,andR132Klacked
affinity for NSC162535. F48Y, however, retained binding affinity
(Kd=12mM; Fig. 1B), whereas R57K had reduced affinity
(Kd=48mM), indicating that replacement with a more conservative
side chain at F48 and R57 partially rescued the binding affinity. In
contrast, the mutants D33A and D33E, and R116A and R116K
had measurable ITC binding profiles with comparable Kd values
(Table1 and Fig.S4B),suggestingthatthe D33carboxylmoietyand
the R116 guanidino group make a lesser contribution to binding of
NSC162535. M10A and E114A also had measurable affinity
(Table 1 and Fig. S4B). These results together suggest that side
chains from R57 and R132, as well as the aromatic ring from F48,
are most crucial in interacting with NSC162535, and that D33 and
R116, which are important for binding to shikimate, contribute less
to the interactions with NSC162535.
Crystal structures of HpSK?SO4, HpSKN S3PNADP and R57A
Crystal structures of HpSK and MtSK have been reported, alone
and in complex with either one or two substrates/products [28–33].
Based on several MtSK crystal structures, Hartmann et al. proposed
a model for the random sequential binding of substrates (ATP and
shikimate) associated with domain movements [32]. Here, we
additionally determined structures of a dimeric HpSK?SO4
(R=22.7%, Rfree=26.0%), HpSKN S3PNADP (R=23.1%,
Rfree=27.7%), and R57A (R=24.6%, Rfree=27.3%) (Fig. 2, 3,
Fig. S6, and Table 2). Overall, these structures have a characteristic
a-b-a fold that consists of the CORE domain (residues 1–31, 61–
108, and 124–162), the SB domain (residues 32–60), and the LID
region (residues 109–123) in the monomer [33] (Fig. 2). The LID
region is most flexible and flips over the binding pocket, in an open
or closed state [33]. For the dimeric HpSK?SO4 structure, the LID
region points upward, and a number of residues cannot be built into
this region (residues 108–118 in subunit A, and 111–117 in subunit
B), implying a disordered region.
The HpSKNS3PNADP structure shows clear electron density for
all residues. Within the binding pocket, there is a large piece of
non-peptide density that can easily be modeled as the product
S3P, and nearby density can be built as ADP (Fig. 2). The final
structure includes an ordered and complete LID segment that
closes over the binding pocket, in accordance with the closed-form
MtSKNS3PNADP structure (2IYZ; root mean square deviation of
Ca atoms=1.26 A ˚) [32]. The LID region covers the binding
pocket in which the guanidino group of R116 has direct contacts
with S3P and the b-phosphate of ADP, forming strong hydrogen
bonds. In the HpSKNshikimateNPO4 structure, R116 also makes a
hydrogen bond with the carboxyl moiety of shikimate. Based on
these structures, it is likely that S3P is chelated by R57 and R132
via a hydrogen-bonding network in HpSKNshikimateNPO4 and
HpSKNS3PNADP. This would lead to a small movement in the
peptide backbone, propagated through the a6 helix into the
adjacent LID loop. A subsequent large conformational rearrange-
ment of this loop would allow the side chain of R116 to bind to the
phosphate group of S3P, as seen in HpSKNS3PNADP, or possibly
the c-phosphate moiety of ATP [32].
We also determined the structure of mutant R57A (Fig. S6 and
Table 2) that lacked enzyme activity. In the wild-type HpSK, the
guanidino group of R57 forms hydrogen bonds with the two
carboxyl groups from E53 and E60. Replacement of the guanidino
side chain with a methyl group at this pocket eliminates these
interactions in R57A. Instead, E53 from the SB domain forms
hydrogen bonds to the guanidino group from R132 (E53 [Oe1]-
R132 [Ng1]: 2.21 A ˚; E53 [Oe2]-R132 [Ng2]: 3.58 A ˚) located at
a6 (CORE). The E53–R132 proximity in R57A appears to induce
a conformational move for the SB domain (residues 43–63; a3, the
a3–a4 loop, and a4) and slightly influences the CORE domain.
Crystal structure of E114A complexed to NSC162535
reveals an inactivation mechanism
In an effort to understand the detailed structure-activity
relationship of this inhibitor at atomic resolution, we attempted
crystallization trials using either wild-type HpSK or a mutant
prepared in this investigation. After extensive trials, only the map of
the E114A?162535 crystal showed a large piece of residual density
in the binding pocket, which could be modeled as NSC162535
(Fig.3 and Fig.S5).ThefinalE114A?162535 crystalstructure shows
a trimeric assembly (R=21.8%, Rfree=26.2%; Table 2).
NSC162535, which is clearly observed in two of the three
subunits, exhibits an extended conformation between LID and SB.
Interestingly, it extends out to the entrance of the binding pocket
(Fig. 2). The LID loop of HpSK accommodates the inhibitor by
undergoing a large conformational switch, distinct from that of
HpSK?SO4 and HpSKN S3PNADP. Notably, the side chain of
R116 at LID forms hydrogen bonds with an SO4 group and packs
against one of the naphthalene moieties with an electron-rich p
system (Table 3). This naphthalene group also packs against the
aromatic ring of F48 from the SB domain on the other side,
establishing strong cation-p and p-p interactions. The other
naphthalene group interacts with the side chain of R132, yielding
a cation-p interaction. Additionally, the guanidino groups of R116
and R57 are located near the diazo moiety of NSC162535,
making cation-p interaction and a kind of polar interaction,
respectively (Fig. 4B). This inhibitor also makes contact with
residues from, or near, the Walker A (F9 and M10) and Walker B
(G80, G81, V83, and M84) motifs, as well as with L135 and Y136
(Fig. 4B). Such strong cation-p, p-p, hydrogen-bonding interac-
tions, and van der Waal contacts between NSC162535 and the
Figure 2. Superposition of four HpSK structures. The following
structures are shown: HpSK?dimer?SO4 (blue), HpSK?shikimate?PO4
(1ZUI) (yellow), HpSK?S3P?ADP (cyan), and E114A?162535 (pink). These
structures show homologous folds but a flexible LID segment.
doi:10.1371/journal.pone.0033481.g002
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tion, as opposed to that seen in the binding pocket of HpSKN
S3PNADP (Fig. 4A). Superposition of HpSKN S3PNADP and
E114N162535 shows that only R57 and R132 stay at approxi-
mately the same position; M10 and R116 are situated at rather
distinct positions to interact with S3P and NSC162535, respec-
tively (Fig. 4 and Table 3). Additionally, HpSKNS3PNADP and
E114N162535 have different contacting residues, (D33, V44, G79,
P117, L118, and F9, R45, F48, V83, M84, L135, Y136,
respectively). Taken together, these data suggest a unique
environment at this position, which explains its inhibitor selectivity
(Fig. 4 and Table 3).
A distinctive induced-fit conformational change of the
inhibitor complex
Superposition of various structures (HpSKNSO4 open form;
HpSKNshikimateNPO4, PDB code 1ZUI [33]; HpSKNS3PNADP
and E114AN162535) reveals a significant conformational change in
the LID-containing segment after the b4 region of the CORE
domain (residues 101–138; a5, LID and a6 regions; Fig. 2).
Furthermore, the SB region (residues 32–60) shows a small
rotation in the different liganded/non-liganded states, in agree-
ment with the MtSK structure [32].
Of the three conserved Arg residues (R57, R116, R132), the Ca
atom of R57 superimposes relatively well, whereas that of R132
has a small shift in the various structures (Fig. 5A–5D). Notably,
there is a significant shift for R116 owing to the distinct
conformations of the LID loop (Fig. 5A–5D). Our results suggest
that these Arg residues contribute to the movement of the LID
region and the SB domain upon binding to shikimate. R116, when
visible, makes a significant shift to contact various ligands in the
binding pocket: (i) shikimate in HpSKNshikimateNPO4; (ii) b-
phosphate of ADP in HpSKNS3PNADP; and (iii) NSC162535 in
E114AN162535. In the MtSKNshikimateNAMPPCP structure (PDB
code: 1ZYU [31]), R117 (corresponding to R116 in HpSK)
directly contacts the c-phosphate group of AMPPCP, an ATP
analog, which supports its catalytic role in the c-phosphoryl
transfer [31].
To evaluate whether NSC162535 would come in contact with
R116 in various conformations, we docked NSC162535 into each
of the HpSK binding pockets (Fig. 5E–5I). In the open form,
HpSK (flexible LID) presents a wide-opening pocket, allowing
entry of promising substrates (Fig. 5A, 5E, and 5J). No close
contacts were found between R116 and the docked NSC162535 in
the binding pockets of the open and HpSKNshikimateNPO4 forms
(Fig. 5E and 5F). In the HpSKNS3PNADP state, NSC162535
docked into a site where there were no direct contacts with the
Ng1 and Ng2 atoms of R116. NSC162535, on the other hand,
docked into a comparable site in the E114AN162535 form; it
directly contacts the Ng1 and Ng2 atoms of R116, demonstrating
a distinctive induced-fit conformation.
Discussion
In this investigation, we compared the shikimate binding
properties of wild-type and mutant HpSKs using ITC. We
Figure 3. Stereoview of the electron density map of NSC162535. (B) is 90 degree rotation clockwise of (A). F48, R57, R116, and R132 are
shown onto superimposed structures [E114A?162535 (pink), HpSK?dimer?SO4 (blue), and HpSK?S3P?ADP (cyan)]. The 2Fo2Fc electron density map
shows the bound NSC162535, contoured at the 1.0-s level.
doi:10.1371/journal.pone.0033481.g003
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to interactions with shikimate, and therefore catalytic activity.
Additionally, side chains from D33 and F48 were found to play
important roles in binding to shikimate. Based on virtual docking
analysis, we were able to design a potent inhibitor, NSC162535,
for this SB pocket, which included these residues. Furthermore, we
solved four HpSK structures: HpSKNSO4, HpSKNS3PNADP,
R57A, and E114AN162535.
Analysis of these structures reveals that R57 is critical for
stabilizing and maintaining the optimal environment, whereas
R132 plays a critical role in chelating the ligand. The R57A
mutant structure shows a notable shift of the SB domain owing to
the interactions between E53 and R132, rather than those
between E53 and R57 in the wild-type structure, revealing a
crucial role for R57 and R132 in defining the best active-site
geometry to accommodate promising substrates (Fig. 3). In support
of this view, R57 stays at a relatively identical site, whereas R132
shifts slightly among superimposed structures (Fig. 3, 5I and 5J).
R116, on the other hand, is located in the flexible LID segment
and shows a significant move among various forms. It is visible in
Table 2. X-ray data collection and refinement statistics.
HpSK?dimer?SO4 HpSK?S3P?ADP HpSK?R57A E114A?162535
PDB code 3HR7 3MUF 3MRS 3N2E
Data collection
Source NSRRC BL-13B1
a NSRRC BL-13C1
a SPring-8 BL-12B2
a SPring-8 BL-12B2
Wavelength (A ˚) 1.000 0.9762 1.000 1.000
Temperature 2165uC 2165uC 2165uC 2165uC
Space group C2 P61 P43212 C2
Cell dimensions
a, b, c (A ˚) 122.48, 59.61, 80.76 98.82, 98.82, 42.13 88.90, 88.90, 39.87 193.91, 71.79, 47.63
a, b, c (u) 90, 113.08, 90 90, 90, 120 90, 90, 90 90, 91.96, 90
Resolution range (A ˚) 30-1.80 (1.86-1.80)
b 30-2.30 (2.38-2.30) 30-2.40 (2.49-2.40) 30-2.53 (2.62-2.53)
Rmerge (%)
c 6.8 (41.8) 6.8 (48.8) 3.8 (13.1) 5.3 (30.5)
I/sI 18.0 (2.6) 29.3 (2.5) 56.0 (19.0) 26.8 (4.3)
Completeness (%) 98.2 (94.1) 99.9 (99.5) 99.8 (100.0) 99.7 (98.3)
Redundancy 3.8 (3.5) 11.7 (10.7) 10.4 (10.6) 5.1 (4.7)
Refinement
Resolution (A ˚) 30.0–1.80 30.0–2.30 30.0–2.40 30.0–2.53
No. reflections 46,105 10,003 6,287 20,807
Rwork
d/Rfree
e 0.227/0.260 0.231/0.277 0.246/0.273 0.218/0.262
No. atoms
Protein 2422 1279 1172 3661
Ligand/ion 10 43 0 116
Water 316 75 25 83
r.m.s. deviation
f
Bond length (A ˚) 0.017 0.018 0.016 0.022
Bond angle (u) 1.546 1.780 1.617 2.018
Overall B factor (A ˚2)
from Wilson plot 27.50 36.00 44.20 40.00
from protein model 29.45 56.19 28.24 44.30
Ramachandran analysis (%)
Favored 99.7 96.8 96.6 97.6
Allowed 0.3 3.2 3.4 2.4
Generous 0.0 0.0 0.0 0.0
Disallowed 0.0 0.0 0.0 0.0
Estimated coordinate error (A ˚) 0.117 0.242 0.537 0.292
All data sets were collected from a single crystal.
aBL-13B1/13C1 National Synchrotron Radiation Research Center (NSRRC), HsinChu, Taiwan; Taiwan BL-12B2 beamline at SPring-8, Hyogo, Japan.
bValues in parentheses refer to statistics in the highest-resolution shell.
cRmerge=g|Iobs2,I.|gIobs.
dR=g|Fobs2Fcalc|/gFobs, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively.
eRfree was computed using 5% of the data assigned randomly.
fr.m.s., root mean square.
doi:10.1371/journal.pone.0033481.t002
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te?PO4, HpSK?S3P?ADP, and E114A?162535), where R116
directly contacts shikimate/S3P/NSC162535. Interestingly, ITC
measurements revealed that this catalytic residue contributes
substantially to shikimate binding but not to that of NSC162535.
The insignificant contribution of R116 to NSC162535 binding
(Table 1) implicates the likelihood that the R116-NSC162535
contacts, seen in the E114?162535 structure, result from induced
conformational positioning.
Based on these results, we hypothesize that R57, in conjunction
with R132, form an environment, along with F48, to interact with
shikimate, triggering a cycle of conformational change. R116 sits
at the LID segment and then contacts shikimate during the course
of a conformational swap cycle to initiate catalysis of the specific
phosphorylation of the 3-hydroxyl group (Fig. 5). Such positioning
is crucial to yield an optimal conformation for R116 to stabilize
the pentavalent transition-state intermediate [31], which allows
catalysis to take place.
In regards to NSC162535 binding, it is likely that when
NSC162535 interacts with R57 and R132, it also prompts a cycle
of conformational change. The stable R57–R132 framework
thereby provides an interacting anchor for not only shikimate/S3P
but also NSC162535, triggering a conformational swap cycle to
initiate a potential enzymatic reaction. Notably, the positioning
optimization to trap NSC162535 yields a remarkably distinctive
conformation, as seen in E114AN162535. Because there were
nearly identical ITC binding data (either shikimate or
NSC162535) between the wild-type and E114A, it is conceivable
that the wild-type enzyme has an analogous binding configuration
Table 3. Binding of shikimate-3-phosphate and NSC162535
to HpSK?S3P?ADP and E114A?162535.
Atom S3P
Distance
(A ˚) Atom NSC162535 Distance (A ˚)
HpSK?S3P?ADP E114A?162535*
CX
Glu53 Oe1 CAP 3.52
Arg57 Ng1 O4 3.29
Arg57 Ng2 O4 3.37 Arg57 Ng2 OAL 3.16
NAM 3.58
NAN 3.28
Arg132 Cb NAG 3.48
Arg132 Cc CAE 3.3
CAF 3.2
NAG 3.33
Arg132 Cd CAD 3.27
CAE 3.15
CAF 3.52
Arg132 Ne CAB 3.54
CAC 3.4
CAD 3.49
Arg132 Cf O4 3.55 Arg132 Cf CAC 3.47
O5 3.36 CAK 3.53
Arg132 Ng1 C7 3.47 Arg132 Ng1 CAI 3.51
O4 3.6 CAJ 3.5
O5 2.61
Arg132 Ng2C 7 3 . 4
O4 2.71
O5 3.36
Leu135 Cc NAG 3.46
Leu135 Cd2 NAG 2.9
Tyr136 Og CAE 3.58
CAH 3.54
OLID
Arg45 Cc OBA 3.17
OBC 3.13
Phe48 Ce1 CAQ 3.56
Arg116 Cc O7 3.48
Arg116 Cd O7 3.53
Arg116 Ne O7 2.53
Arg116 Cf O7 3.13 Arg116 Cf CAT 3.58
Arg116 Ng1 OBG 3.26
Arg116 Ng2 O7 3.02 Arg116 Ng2 OBG 3.15
Pro117 Cd O3 3.54
Leu118 Cd1 O4 3.31
OCORE
Phe9 Cd1 OBE 3.55
Met10 N OBE 3.46
Met10 Cc O7 3.4
Lys14 Nf O8 2.74
Asp33 Cc O2 3.59
Asp33 Od1 O2 3.04
Table 3. Cont.
Atom S3P
Distance
(A ˚) Atom NSC162535 Distance (A ˚)
Asp33 Od2 C4 3.36
O1 3.17
O2 3.35
O6 3.45
Gly79 Ca O1 3.47
O2 3.5
Gly80 N C2 3.17
O1 3.09
O8 2.99
Gly80 Ca C2 3.45 Gly80 Ca OBE 3.32
O5 3.1 OBF 3.46
O8 3.52
Gly80 C O5 3.13 Gly80 C CAH 3.46
Gly80 O CAH 3.48
Gly81 N C7 3.35
O5 3.19
Gly81 Ca O4 3.56 Gly81 Ca CAC 3.59
O5 3.59
Val83 Cc1 NAG 3.42
Met84 Ce CAA 3.53
CAB 2.93
OAL 3.54
*Atom notation is given in Figure S5.
doi:10.1371/journal.pone.0033481.t003
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fits this inhibitor; R116 subsequently comes into contact with the
SO4 group, locking into a distinctive induced form as seen in the
complex structure.
Materials and Methods
Preparation of mutant HpSKs
Site-directed mutagenesis was performed using the overlap
extension PCR method [39] with the plasmid pQE30-HpSK as
the template. All mutations were confirmed by sequencing of the
whole ligated PCR fragment. Mutant proteins were expressed and
purified by the same procedures as based on published methods
for HpSK [33].
Enzymatic activity of wild-type and mutant HpSKs
SK activity was determined by coupling the release of ADP
from the SK-catalyzed reaction to the oxidation of NADH using
pyruvate kinase (EC 2.7.1.40) and lactate dehydrogenase (EC
1.1.1.27) as coupling enzymes. Shikimate-dependent oxidation of
NADH was monitored by a decrease in A340
(e=6,200 M
21 cm
21). The assay was carried out at 25uCi na
mixture containing 100 mM Tris-HCl, pH 7.5, 50 mM KCl,
5 mM MgCl2, 1.6 mM shikimic acid, 2.5 mM ATP, 1 mM
phosphoenolpyruvate, 0.1 mM NADH, 2.5 U ml
21 pyruvate
kinase, and 2.7 U ml
21 lactate dehydrogenase. All assays were
conducted in a 96-well microplate and analyzed with a
spectrophotometer (FLUOstar OPTIMA, BMG LABTECH).
The relative activity of wild-type HpSK was set to 100%.
Differential scanning calorimetry (DSC)
DSC measurements were carried out using a VP-DSC
Microcalorimeter (Microcal, Northampton, MA). The HpSK
proteins were in 40 mM Tris-HCl (pH 7.0) containing 100 mM
NaCl. The DSC experiments were performed at a concentration
of 0.1 mM HpSK protein. Prior to making measurements, a
baseline was established by repeated scans of the sample cell
containing only buffer solution. Scans were performed from low to
high temperatures, at a rate of change of temperature of 1.0uC
min
21. A buffer-buffer scan was subtracted from the buffer-sample
scans, and linear-polynomial baselines were drawn for each scan.
Baseline-corrected thermograms were then normalized to obtain
the corresponding molar heat capacity curves. Midpoint temper-
ature (Tm) values were estimated as the temperatures correspond-
ing to the maximum of each thermogram peak. Analysis of DSC
thermograms was implemented using Origin
TM Software.
Isothermal titration calorimetry (ITC)
Titration experiments were performed by ITC using an iTC200
or VP-ITC instrument (MicroCal, Piscataway, NJ, USA), and a
0.2-ml (iTC200) or 1.4-ml (VP-ITC) sample cell containing the
macromolecule solution. All proteins were prepared in a buffer
containing 20 mM potassium phosphate, pH 7.3. Prior to the
experiment, samples were filtered and degassed under vacuum for
10 min in a Thermo Vac system (Microcal). The sample cell was
filled with sample protein solution (15 mM) or the working buffer.
Procedures of iTC200 titrations with a ligand (450 mM) were as
follows: an initial 1-ml injection (not included in data analysis)
followed by 19 injections of 2 ml each, with 2-min intervals
between injections. Similar procedures for VP-ITC titrations were
also performed: an initial 2-ml injection followed by 24 injections of
10 ml each, with 3-min intervals between injections. The
experiments were performed with a constant stirrer speed of
1000 rpm (iTC200) or 290 rpm (VP-ITC) at 25uC. The binding
isotherms were fitted to a one-site binding model to obtain the
thermodynamic parameters with the initial point discarded. Data
analysis was conducted using Origin 7 software.
Crystallization and data collection
Crystallization was performed in 96-well microplates at 20uC
using an Oryx8 robotic system (Douglas Instruments Ltd). The
volume of HpSK protein solution (50 mg ml
21) in 40 mM Tris-
Figure 4. Schematic illustration of HpSK?S3P?ADP and E114A?162535 binding pockets. (A) Residues that contact S3P and ADP in
HpSK?S3P?ADP. Red dashed lines denote hydrogen-bonding interactions. (B) Residues that contact NSC162535 in E114A?162535. Dotted green lines
and blue curves are cation-p and p-p interactions, respectively. Residues from three HpSK?shikimate?PO4 subsites, CX,O CORE, and OLID [33], are colored
by cyan, yellow, and pink, respectively. Residues from the nucleotide site are colored by grey.
doi:10.1371/journal.pone.0033481.g004
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solution and equilibrated against 60 ml of reservoir solution. Initial
crystallization conditions were screened using 672 different kit
solutions (Hampton Research, Molecular Dimension and Jena
Bioscience). We observed many different crystal forms in the
drops.
The condition of HpSK?SO4 crystals was similar to that of apo
HpSK crystals [33], which were obtained in buffer containing 0.2
ML i 2SO4, 30% (w/v) polyethylene glycol (PEG) 8000, and 0.1 M
sodium acetate buffer (pH 6.5). Crystals of HpSK?S3P?ADP,
added to 5 mM shikimate and 5 mM MgATP, were obtained
from 0.1 M HEPES sodium salt (pH 7.5), 0.1 M sodium acetate,
18% (w/v) PEG 8000 and 2% (w/v) 2-propanol. HpSK?R57A
crystals were grown in a hanging-drop containing 0.1 M HEPES
sodium salt (pH 8.0), 8% (w/v) 2-propanol and 18% (w/v)
PEG4000. The best crystals of the E114A?162535 structure were
obtained in a modified condition, containing 0.1 M HEPES
sodium salt (pH 6.7) and 1.2 M potassium sodium tartrate
tetrahydrate. Prior to data collection, crystals were dipped into
Fomblin cryoprotectant oil for several seconds and then flash-
frozen in a liquid nitrogen stream. The X-ray diffraction data were
collected on NSRRC BL-13B1, BL-13C1, and SPring-8 BL-12B2
Figure 5. Probing the binding pockets in HpSK. (A–D) The binding pockets of HpSK: (A) open HpSK (3HR7), (B) HpSK?shikimate?PO4 (1ZUI), (C)
HpSK?S3P?ADP (3MUF), and (D) E114A?162535 (3N2E). The bound ligands, D33, F48, R57, R116, and R132 are drawn as sticks. The LID segments
(residues 109–123) are drawn as ribbon structures. (E–H) The docked NSC162535 models in the binding pockets of HpSK: (E) open HpSK, (F)
HpSK?shikimate?PO4, (G) HpSK?S3P?ADP, and (H) E114A?162535. Superposition of the three residues R57, R116, and R132, docked and bound to
NSC162535 with open HpSK (blue), HpSK?shikimate?PO4 (yellow), HpSK?S3P?ADP (cyan), and E114A?162535 (pink). (I) Superimposed docked
structures (E–H). The conformation of the LID segment (residues 113–119, shown as ribbon) and R116 (thick stick) demonstrates the greatest
conformational changes induced by bound ligands. (J) Schematic diagram of induced-fit conformational changes upon ligand binding. The view of
LID regions corresponding to open HpSK (e), HpSK?S3P?ADP (g), and E114A?162535 (h) are colored as blue, cyan, and pink, respectively.
doi:10.1371/journal.pone.0033481.g005
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collected at 2150uC and processed with the HKL/HKL2000
software suite [40]. Data collection statistics are shown in Table 2.
Structure determination and refinement
The four structures were solved by molecular replacement with
the program MOLREP [41] using the structure of the apo form of
HpSK (PDB code, 1ZUH) as the search model. Further
refinement was carried out using the maximum-likelihood target
function embedded in the program REFMAC5 [42] and coupled
to ARP/wARP [43]. Five percent of the reflections were randomly
selected and used to compute a free R value (Rfree) for cross-
validation of the model. 2Fo2Fc and Fo2Fc maps were produced
and inspected after each cycle of refinement to revise the model
manually on an interactive graphics computer with the program
Coot [44]. The overall stereochemical quality of the final model
was assessed with the program PROCHECK [45]. The atomic
coordinates and structure factors were deposited in the RCSB
Protein Data Bank with accession code 3HR7 (HpSK?SO4),
3MUF (HpSK?S3P?ADP), 3MRS (HpSK?R57A) and 3N2E
(E114A?162535) (Table 2).
Structural comparisons
Comparison with the six HpSK structures (PDB codes, 1ZUH
[33], 1ZUI [33], 3HR7, 3MUF, 3MRS, 3N2E) and other SKs
were carried out using the program LSQMAN in O [46] to
superimpose Ca atoms, based on the optimized alignment.
Structural figures were prepared with the program PyMOL.
Molecular docking
The binding site for virtual docking screening of putative
inhibitors was determined by considering the protein atoms
located #10 A ˚ from the SB site of MtSK (open-form structure;
PDB code: 2IYT) and HpSK (open-form structure; PDB code:
1ZUH), respectively. We programmed GEMDOCK [38,47–49]
to screen Maybridge (65,947 compounds) and NCI (236,962
compounds) databases for both HpSK and MtSK. Top ranked
compounds (n=20) with the lowest energies were selected for
testing in the enzyme inhibitory assay.
GEMDOCK was also used to dock NSC162535 to each of the
four HpSK structures (HpSK?SO4, HpSK?shikimate?PO4,
HpSK?S3P?ADP, and E114A?162535).
Supporting Information
Figure S1 Superposition of nine shikimate kinases. The
apo- and closed-HpSK (PDB codes: 1ZUH and 3MUF) are shown
in blue and cyan, respectively. Apo form of MtSK (PDB code:
2IYT) is shown in orange, and closed-form (PDB code: 2IYQ) in
yellow. The EcSK (PDB code: 1SHK) is red, and the EcSK
complexed with ADP (PDB code: 2SHK) is pink. Green, brown
and gray are indicated in CjSK (PDB code: 1VIA), EcoSK (PDB
code: 1KAG) and AaSK (PDB code: 2PT5), respectively. (Hp:
Helicobacter pylori; Mt: Mycobacterium tuberculosis; Ec: Erwinia
chrysanthemi; Cj: Campylobacter jejuni; Eco: Escherichia coli; Aa: Aquifex
aeolicus).
(TIF)
Figure S2 Conserved residues of SKs and structure-
based alignment of HpSK and MtSK. Six shikimate kinases
(E. coli, E. chrysanthemi, C. jejuni, A. aeolicus, M. tuberculosis and H.
pylori) are aligned and shown with WebLogo program (http://
weblogo.berkeley.edu/). HpSK and MtSK alignment are shown
with ESPript program (http://espript.ibcp.fr/ESPript/ESPript/).
The secondary structural elements are shown above the sequence.
Mutants generated for the structure-activity analyses are indicated
below the aligned sequence. Three arginines (R57, R116, and
R132) belong to CX shikimate-binding subsite. OCORE consists of
M10 and D33; and OLID consists of F48, E114, and R116.
(TIF)
Figure S3 DSC heat capacity curve of HpSK proteins.
(TIF)
Figure S4 Binding properties of HpSK mutants. Isother-
mal titration calorimetry data showing (A) the titration of
shikimate into M10A mutant; (B) the titration of NSC162535
into M10A, D33A, D33E, R57K, E114A and R116A.
(TIF)
Figure S5 Chemical structure of NSC162535.
(TIF)
Figure S6 Conformational movement in the SB domain
of HpSK?R57A structure. A stereo view of the superimposed
binding pocket between open HpSK (blue) and R57A (magenta)
structures is shown. The oxygen, nitrogen and phosphorus atoms
are colored red, blue and orange, respectively. The dashed line
indicates hydrogen bonds.
(TIF)
Table S1 DSC thermodynamic parameters for the melting of
HpSK wild-type and its mutants.
(DOC)
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